Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Loss of Zap-70 and low molecular weight phosphotyrosine phosphatase occurs after therapy in a patient with B-chronic lymphocytic leukemia

Leukemia volume 19, pages 1503–1505 (2005)Cite this article

TO THE EDITOR

Zap-70 is a tyrosine kinase involved in B-cell receptor signaling in chronic lymphocytic leukemia cells.1 Activation of Zap-70 occurs after phosphorylation of specific tyrosine residues.2 Dephosphorylation of tyrosine-292, a negative regulatory site, on Zap-70 also activates the kinase activity.3 Although many of the binding partners of low molecular weight phosphotyrosine phosphatase (LMWPTP) have been characterized, the biological function of LMWPTP remains vague. Although not well characterized in chronic lymphocytic leukemia, overexpression of LMWPTP is generally associated with a proliferative phenotype.4 LMWPTP has been shown to interact with several tyrosine kinases including the platelet-derived growth factor receptor, the macrophage colony-stimulating factor receptor, the insulin receptor, the Eph receptor, and the epidermal growth factor receptor.5 Since LMWPTP also interacts with Zap-70,3 we followed the expression of activated Zap-70 and LMWPTP in a patient with chronic lymphocytic leukemia.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Chen L, Widhopf G, Huynh L, Rassenti L, Rai KR, Weiss A et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2002; 100: 4609–4614.

    Article  CAS  Google Scholar 

  2. Watts JD, Affolter M, Krebs DL, Wange RL, Samelson LE, Aebersold R . Identification by electrospray ionization mass spectrometry of the sites of tyrosine phosphorylation induced in activated Jurkat T cells on the protein tyrosine kinase ZAP-70. J Biol Chem 1994; 269: 29520–29529.

    CAS  PubMed  Google Scholar 

  3. Bottini N, Stefanini L, Williams S, Alonso A, Jascur T, Abraham RT et al. Activation of ZAP-70 through specific dephosphorylation at the inhibitory Tyr-292 by the low molecular weight phosphotyrosine phosphatase (LMPTP). J Biol Chem 2002; 277: 24220–24224.

    Article  CAS  Google Scholar 

  4. Chiarugi P, Taddei ML, Schiavone N, Papucci L, Giannoni E, Fiaschi T et al. LMW-PTP is a positive regulator of tumor onset and growth. Oncogene 2004; 23: 3905–3914.

    Article  CAS  Google Scholar 

  5. Miller DT, Read R, Rusconi J, Cagan RL . The Drosophila primo locus encodes two low-molecular-weight tyrosine phosphatases. Gene 2000; 243: 1–9.

    Article  CAS  Google Scholar 

  6. Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson SE et al. M. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome and distinct gene expression profile. Blood 2003; 101: 4944–4951.

    Article  CAS  Google Scholar 

  7. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910–1916.

    Article  CAS  Google Scholar 

  8. Rassenti LZ, Huynh L, Toy TL, Chen L, Keating MJ, Gribben JG et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004; 351: 893–901.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Dr Z Chen has been supported in part by the Chinese National Key Program for Basic Research (973, 001CB510103) and a grant from the Chinese National Science Fund for Distinguished Young Scholars (30225038). Dr M Yu has been supported by the American Society of Clinical Oncology Clinical Research Career Development Award and the Huntsman Cancer Institute Translational Research Program.

Author information

Authors and Affiliations

  1. Division of Medical Genetics, Department of Pediatrics, School of Medicine, Salt Lake City, UT, USA

    Z Chen & E Aston

  2. Members of the University of Utah Lymphoproliferative Disease Group, School of Medicine, Salt Lake City, UT, USA

    Z Chen, E Aston & M K Yu

  3. Division of Medical Oncology, Department of Internal Medicine, School of Medicine, Salt Lake City, UT, USA

    M K Yu

Authors
  1. Z Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E Aston
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M K Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M K Yu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chen, Z., Aston, E. & Yu, M. Loss of Zap-70 and low molecular weight phosphotyrosine phosphatase occurs after therapy in a patient with B-chronic lymphocytic leukemia. Leukemia 19, 1503–1505 (2005). https://doi.org/10.1038/sj.leu.2403793

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403793

This article is cited by

Search

Advanced search

Quick links